Search

Global Computational Biology & Digital Sciences

Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.

FDA- HFpEF-breakthrough-designation-EMPEROR-preserved

U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction

Phase II trial results in people living with obesity or overweight

Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas

Zongertinib positive results non-small cell lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Tackling NCDs through innovation AND collaboration

Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them

Boehringer-Ingelheim's-half-year-figures-2021

Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.

2024 half year results innovation progress

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.

EMPA-KIDNEY trial early stop due to positive efficacy

EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Ileitis prevention vaccination Lawsonia intracellularis pig

Cause, impact and prevention: Learn the essentials about Ileitis

Phase II clinical trial weight loss results

Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)

Boehringer Ingelheim half-year results 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer_Ingelheim_Annual_Report_2018.pdf

Boehringer-Ingelheim_Annual_Report_2020.pdf

Annual_Report_2022_consolidated-companies_EN

BoehringerIngelheim_Annual_Report_2014.pdf